Search

Displaying results 4001 - 4010 of 9705 in total
  1. Drug

    Levomethadone

    go.drugbank.com/drugs/DB13515
    Investigational

    Synonyms: l-methadoneProducts: L-Polamidon 20 mg Tabletten, L-Polamidon 5 mg Tabletten
  2. Drug

    Metergoline

    go.drugbank.com/drugs/DB13520
    Approved

    Metergoline is an ergot-derived psychoactive drug that acts as a ligand for serotonin and dopamine receptors. … Metergoline is an antagonist at various 5-HT receptor subtypes at a relatively low concentration and agonist at dopamine receptors.

  3. Drug

    Isepamicin

    go.drugbank.com/drugs/DB13540
    Experimental

    Categories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index
  4. Drug

    4-dimethylaminophenol

    go.drugbank.com/drugs/DB13549
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Diethyl ether

    go.drugbank.com/drugs/DB13598
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Deltamethrin

    go.drugbank.com/drugs/DB13600
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Montmorillonite

    go.drugbank.com/drugs/DB13654
    Investigational

    Categories: Compounds used in a research, industrial, or household settingProducts: IMPIDEM® POLVO PARA RECONSTITUIR A SOLUCION ORAL, DIOSMECTITA 3 G POLVO PARA RECONSTITUIR A SUSPENSIÓN ORAL
  8. Drug

    Niaprazine

    go.drugbank.com/drugs/DB13687
    Investigational

    Niaprazine is a selective brain catecholamine depletor.

  9. Drug

    Apalutamide

    go.drugbank.com/drugs/DB11901
    ApprovedInvestigational

    In a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo [L1295]. … Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death [A31846].

  10. Drug

    Lebrikizumab

    go.drugbank.com/drugs/DB11914
    ApprovedInvestigational

    Lebrikizumab is a monoclonal antibody that binds to IL-13 with high affinity and slow off-rate.[L51374] It binds to a different epitope compared [tralokinumab]. … November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12 years and older with a